BioLife Solutions, Inc.

BioLife Solutions, Inc.(BLFS)股票分析

$38.610

+1.355 (+3.51%)收盤時

Loading chart…
最高
38.830
開盤
37.160
成交量加權均價
38.13
成交量
4.45M
市值
944.41M
最低
36.950
成交金額
169.53M
企業價值/稅息折舊攤銷前利潤(TTM)
164.02

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

AI 分析 of BioLife Solutions, Inc. (BLFS)

持有

BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.

分析師評級(3)

-13.88% 下跌空間
買進
2 買進
1 持有
0 賣出
目前: 38.61
最低
32.00
平均
33.25
最高
34.00

Benchmark

2026-08-10

目標價

—

持有

Jefferies

2026-07-23

目標價

$31

持有

H.C. Wainwright

2026-07-23

目標價

$31

中性

TD Cowen

2026-07-22

目標價

$31

持有

Craig-Hallum

2026-07-22

目標價

$31

持有

估值指標

BioLife Solutions, Inc.(BLFS)目前預期本益比為 238.10,5 年平均預期本益比為 -160.71。

預期本益比

合理
5 年均值 P/E
-160.71
目前P/E
238.10
高估
737.12
低估
-1058.54

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
78.61
目前EV/EBITDA
164.02
高估
194.03
低估
-36.80

預期股價營收比

高估
5 年均值 P/S
8.26
目前P/S
14.01
高估
11.35
低估
5.16

Alphio AI 對 BLFS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BLFS

$26.69

情境價格

基

基準

基準 · 50%BLFS

$21.52

情境價格

悲

悲觀

悲觀 · 25%BLFS

$21.37

情境價格

持有 BLFS 的大戶

C

Cramer Rosenthal McGlynn LLC

+ 持有BLFS

-5.04%

3個月報酬率

事件時間軸

2026-10-05 (ET)

17:30:00

Repligen Acquires BioLife Solutions

2026-07-27 (ET)

08:00:00

Stephens Downgrades BioLife Solutions Price Target to $31

2026-07-22 (ET)

16:31:00

Major Averages Close Fractionally Lower as Traders Remain Cautious

15:00:00

Maxim Downgrades BioLife Solutions to Hold After Repligen's $31 Acquisition

12:30:00

Major Averages Mixed as Oil Prices Surge Again

資訊

BLFS 常見問題 —— 由 Alphio AI 解答

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.

3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易